Russell Greig, former president of GlaxoSmithKline’s venture capital arm, has been appointed chair of the supervisory board of AM-Pharma BV of the Netherlands, a company with products in development to treat acute kidney injury. Prior to joining SR One, the GSK venture capital arm, Dr Greig was president of international pharmaceuticals at the UK multinational and also a member of the GSK corporate executive team. At the same time, Eric Claassen is stepping down from the supervisory board, having been chairman for more than 10 years.
Copyright 2012 Evernow Publishing Ltd